Medical device manufacturer St. Jude Medical announced that it has gained European CE Mark approval for its AMPLATZER Amulet Left Atrial Appendage Occluder, a new cardiac device that can prevent heart stroke.

According to the US-based firm , the new device can be fixed at the left atrial appendage (LAA) in patients diagnosed with non-valvular atrial fibrillation (AF).

The firm calims that the new product will prevent blood cloting risk and help in releasing it with reducing the risk of heart stroke.

The new percutaneous transcatheter device is designed on the basis of the original AMPLATZER Cardiac Plug and updated with a longer lobe and waist, which is suitable in treating a wider range of appendage anatomies

The AMPLATZER Amulet device is offered in eight sizes to accommodate varying anatomies.

St. Jude Medical cardiovascular and ablation technologies division president Frank Callaghan said the firm’s new device was built on the basis of feedback from implanting physicians, who used the firm’s first-generation product.

"We are pleased to offer a next-generation LAA occluder that addresses a wider range of patient anatomies, is easier to implant, and has the potential to further reduce the incidence of stroke in AF patients," Callaghan added.